Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals, Inc. - Common Stock
(NQ:
ALNY
)
329.33
+14.94 (+4.75%)
Streaming Delayed Price
Updated: 10:56 AM EST, Feb 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
↗
October 14, 2025
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
↗
October 11, 2025
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the potential catalysts driving attention.
Via
Benzinga
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
October 08, 2025
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...
Via
MarketMinute
Earnings Scheduled For October 30, 2025
↗
October 30, 2025
Via
Benzinga
Uncovering Potential: Alnylam Pharmaceuticals's Earnings Preview
↗
October 29, 2025
Via
Benzinga
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
↗
October 27, 2025
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.
Via
Benzinga
Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest
↗
October 21, 2025
Via
Benzinga
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
October 16, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout
↗
October 07, 2025
Alnylam Pharmaceuticals (ALNY) presents a strong technical breakout setup with a high rating for both trend momentum and consolidation quality.
Via
Chartmill
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know
↗
October 06, 2025
Via
Benzinga
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
October 01, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
September 29, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
↗
September 26, 2025
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam...
Via
Benzinga
Pharma Tariffs Back In Spotlight On New Trump Threat
↗
September 26, 2025
President Donald Trump threatened 100% tariffs on some drug imports.
Via
Investor's Business Daily
Topics
ETFs
Government
World Trade
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
↗
September 25, 2025
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary...
Via
Benzinga
Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock
↗
September 19, 2025
Via
Benzinga
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
September 09, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
September 08, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
↗
September 08, 2025
Via
Benzinga
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
↗
September 02, 2025
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
↗
September 02, 2025
Via
Benzinga
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
August 31, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
August 30, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
August 27, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics
↗
August 22, 2025
Via
Benzinga
How Is The Market Feeling About Alnylam Pharmaceuticals?
↗
August 13, 2025
Via
Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today
↗
August 13, 2025
Via
Benzinga
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
August 11, 2025
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Where Alnylam Pharmaceuticals Stands With Analysts
↗
August 07, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
